LEADER 01569nas1 2200433 450 001 990003216760203316 005 20090409114128.0 035 $a000321676 035 $aUSA01000321676 035 $a(ALEPH)000321676USA01 035 $a000321676 100 $a20090409f---0---9km-y0itay50------ba 101 $aita 102 $aIT 105 $ay|||z|||001yy 200 1 $a<> elfi 210 $aVenezia$cMarsilio 215 $av.$d18 cm 801 0$aIT$bsalbc$gISBD 912 $a990003216760203316 951 $aVII.2. Coll. 8/ 959 $aBK 969 $aUMA 979 $aANNAMARIA$b90$c20090409$lUSA01$h1141 996 $aElfi$91011555 997 $aUNISA 998 \\$1001990000664310203316$12001 $aTorquato Tasso 998 \\$1001990000686920203316$12001 $a<> povero suonatore 998 \\$1001990000742260203316$12001 $aMinna von Barnhelm, ovvero La fortuna del soldato$ecommedia in cinque atti 998 \\$1001990001100000203316$12001 $a<> morte a Venezia 998 \\$1001990001103670203316$12001 $aCristallo di rocca 998 \\$1001990001105710203316$12001 $aLenz 998 \\$1001990001122020203316$12001 $aPentesilea 998 \\$1001990002090870203316$12001 $a<> biondo Eckbert 998 \\$1001990002777970203316$12001 $a<> turbamenti dell'allievo Törleß 998 \\$1001990003300280203316$12001 $aMichael Kohlhaas 998 \\$1001990003574140203316$12001 $a<> gita delle ragazze morte 998 \\$1001990003633560203316$12001 $aIfigenia in Tauride 998 \\$1001990003650510203316$12001 $aElettra LEADER 01369nam a22003257i 4500 001 991001837459707536 008 050703s2005 it 100 0 ita d 020 $a8878700290 035 $ab13434858-39ule_inst 040 $aDip. SSC$bita 082 14$a860 245 00$aStoria politica e storia sociale come fonti creative :$bdue centenari : Pablo Neruda e Alejo Carpentier : atti del convegno di Milano, 22-23 novembre 2004 /$ca cura di Clara Camplani, Patrizia Spinato Bruschi. 260 $aRoma :$bBulzoni,$c2005. 300 $a240 p. ;$c24 cm. 500 $aAtti del convegno. 500 $aIn testa al front.: Istituto di storia dell'Europa ... 500 $aIn cop.: Istituto nazionale ... 504 $aCont. riferimenti bibl. 650 4$aCarpentier, Alejo$xCelebrazioni 650 4$aCarpentier, Alejo$xCongressi$zMilano$y2004 650 4$aNeruda, Pablo$xCelebrazioni 650 4$aNeruda, Pablo$xCongressi$zMilano$y2004 700 1 $aCamplani, Clara. 700 1 $aSpinato Bruschi, Patrizia. 907 $a.b13434858$b21-09-06$c05-09-06 912 $a991001837459707536 945 $aLE021 CAFR13A4$g1$i2021000115660$lle021$nTurano$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i14286804$z06-09-06 996 $aStoria politica e storia sociale come fonti creative$91098071 997 $aUNISALENTO 998 $ale021$b05-09-06$cm$da $e-$fita$git $h0$i0 LEADER 05328nam 22006494a 450 001 9910830504303321 005 20230617040612.0 010 $a1-280-27719-X 010 $a9786610277193 010 $a0-470-35561-1 010 $a0-471-74013-6 010 $a0-471-72781-4 035 $a(CKB)1000000000297443 035 $a(EBL)232612 035 $a(OCoLC)475938695 035 $a(SSID)ssj0000123720 035 $a(PQKBManifestationID)11132685 035 $a(PQKBTitleCode)TC0000123720 035 $a(PQKBWorkID)10008649 035 $a(PQKB)11122381 035 $a(MiAaPQ)EBC232612 035 $a(MiAaPQ)EBC4037039 035 $a(EXLCZ)991000000000297443 100 $a20050214d2005 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aClinical trials$b[electronic resource] $ea methodologic perspective /$fSteven Piantadosi 205 $a2nd ed. 210 $aHoboken, N.J. $cWiley-Interscience$dc2005 215 $a1 online resource (717 p.) 225 1 $aWiley series in probability and statistics 300 $aDescription based upon print version of record. 311 $a0-471-74012-8 320 $aIncludes bibliographical references (p. 613-658 ) and indexes. 327 $aCLINICAL TRIALS; CONTENTS; Preface; Preface to the First Edition; 1 Preliminaries; 1.1 Introduction; 1.2 Audience and Scope; 1.3 Other Sources of Knowledge; 1.3.1 Terminology; 1.3.2 Review of Notation and Terminology Is Helpful; 1.4 Examples, Data, and Programs; 1.5 Summary; 2 Clinical Trials as Research; 2.1 Introduction; 2.1.1 Clinical Reasoning Is Based on the Case History; 2.1.2 Statistical Reasoning Emphasizes Inference Based on Designed Data Production; 2.1.3 Clinical and Statistical Reasoning Converge in Research; 2.2 Defining Clinical Trials Formally 327 $a2.2.1 Mixing of Clinical and Statistical Reasoning Is Recent2.2.2 Clinical Trials Are Rigorously Defined; 2.2.3 Experiments Can Be Misunderstood; 2.2.4 Clinical Trials as Science; 2.2.5 Trials and Statistical Methods Fit within a Spectrum of Clinical Research; 2.3 Practicalities of Usage; 2.3.1 Predicates for a Trial; 2.3.2 Trials Can Provide Confirmatory Evidence; 2.3.3 Clinical Trials Are Unwieldy, Messy, and Reliable; 2.3.4 Other Methods Are Valid for Making Some Clinical Inferences; 2.3.5 Trials Are Difficult to Apply in Some Circumstances; 2.3.6 Randomized Studies Can Be Initiated Early 327 $a2.4 Summary2.5 Questions for Discussion; 3 Why Clinical Trials Are Ethical; 3.1 Introduction; 3.1.1 Science and Ethics Share Objectives; 3.1.2 Equipoise and Uncertainty; 3.2 Duality; 3.2.1 Clinical Trials Sharpen, but Do Not Create, the Issue; 3.2.2 A Gene Therapy Tragedy Illustrates Duality; 3.2.3 Research and Practice Are Convergent; 3.2.4 The Hippocratic Tradition Does Not Proscribe Clinical Trials; 3.2.5 Physicians Always Have Multiple Roles; 3.3 Historically Derived Principles of Ethics; 3.3.1 Nuremberg Contributed an Awareness of the Worst Problems 327 $a3.3.2 High-Profile Mistakes Were Made in the United States3.3.3 The Helsinki Declaration Was Widely Adopted; 3.3.4 Other International Guidelines Have Been Proposed; 3.3.5 Institutional Review Boards Provide Ethical Oversight; 3.3.6 Ethical Principles Relevant to Clinical Trials; 3.4 Contemporary Foundational Principles; 3.4.1 Collaborative Partnership; 3.4.2 Scientific Value; 3.4.3 Scientific Validity; 3.4.4 Fair Subject Selection; 3.4.5 Favorable Risk-Benefit; 3.4.6 Independent Review; 3.4.7 Informed Consent; 3.4.8 Respect for Subjects; 3.5 Methodologic Reflections 327 $a3.5.1 Practice Based on Unproven Treatments Is Not Ethical3.5.2 Ethics Considerations Are Important Determinants of Design; 3.5.3 Specific Methods Have Justification; 3.6 Professional Conduct; 3.6.1 Conflict of Interest; 3.6.2 Professional Statistical Ethics; 3.7 Summary; 3.8 Questions for Discussion; 4 Contexts for Clinical Trials; 4.1 Introduction; 4.1.1 Some Ways to Learn about Trials in a Given Context; 4.1.2 Issues of Context; 4.2 Drugs; 4.2.1 Are Drugs Special?; 4.2.2 Why Trials Are Used Extensively for Drugs; 4.3 Devices; 4.3.1 Use of Trials for Medical Devices 327 $a4.3.2 Are Devices Different from Drugs? 330 $aLearn rigorous statistical methods to ensure valid clinical trialsThis Second Edition of the critically hailed Clinical Trials builds on the text's reputation as a straightforward and authoritative presentation of statistical methods for clinical trials. Readers are introduced to the fundamentals of design for various types of clinical trials and then skillfully guided through the complete process of planning the experiment, assembling a study cohort, assessing data, and reporting results. Throughout the process, the author alerts readers to problems that may arise during the course of 410 0$aWiley series in probability and statistics. 606 $aClinical trials$xStatistical methods 615 0$aClinical trials$xStatistical methods. 676 $a610/.72 676 $a615.50724 700 $aPiantadosi$b Steven$01720612 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830504303321 996 $aClinical trials$94119433 997 $aUNINA LEADER 01416nas 2200445-a 450 001 9910895617003321 005 20241028213016.0 035 $a(DE-599)ZDB2478312-2 035 $a(CKB)110975506069181 035 $a(CONSER)---52033049- 035 $a(DcWaBHL)6193 035 $a(EXLCZ)99110975506069181 100 $a20750726a19169999 --- a 101 0 $aeng 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aMemoirs of the American Entomological Society 210 $aPhiladelphia $cAmerican Entomological Society$d1916- 215 $a1 online resource 311 08$aPrint version: Memoirs of the American Entomological Society. 0065-8170 (DLC) 52033049 (OCoLC)1479819 531 $aAMERICAN ENTOMOLOGICAL SOCIETY MEMOIRS 531 $aMEM AM ENTOMOL SOC 531 0 $aMem. Am. Entomol. Soc. 606 $aEntomology 606 $aEntomologie$vPériodiques 606 $aEntomology$2fast$3(OCoLC)fst00912735 606 $aEntomologie$2gtt 608 $aMonografische Reihe$2gnd-content 615 0$aEntomology. 615 6$aEntomologie 615 7$aEntomology. 615 17$aEntomologie. 676 $a595.7082 712 02$aAmerican Entomological Society. 906 $aJOURNAL 912 $a9910895617003321 920 $aexl_impl conversion 996 $aMemoirs of the American Entomological Society$9791510 997 $aUNINA LEADER 03504nam 2200589Ia 450 001 9910960620403321 005 20251117075845.0 010 $a1-61209-483-X 035 $a(CKB)2670000000129590 035 $a(EBL)3019134 035 $a(SSID)ssj0000691142 035 $a(PQKBManifestationID)12281491 035 $a(PQKBTitleCode)TC0000691142 035 $a(PQKBWorkID)10628632 035 $a(PQKB)11468122 035 $a(MiAaPQ)EBC3019134 035 $a(Au-PeEL)EBL3019134 035 $a(CaPaEBR)ebr10662941 035 $a(OCoLC)761314762 035 $a(BIP)32691748 035 $a(EXLCZ)992670000000129590 100 $a20100927d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aLung transplantation $etherapies, complications, and outcomes /$feditors, Richard D. Ferguson and Craig A. Holmer 205 $a1st ed. 210 $aHauppauge, N.Y. $cNova Science Publishers$dc2011 215 $a1 online resource (241 p.) 225 0 $aOrgan transplantation research horizons 300 $aDescription based upon print version of record. 311 08$a1-61122-760-7 320 $aIncludes bibliographical references and index. 327 $aPrimary graft dysfunction in lung transplantation / S.F. Marasco ... [et al.] -- Intensive care management of the lung transplant recipient / Paolo Feltracco ... [et al.] -- Impact of viral pathogens in lung transplant recipients / Cristina Costa ... [et al.] -- Identification of allo- and auto-antibodies after lung transplantation / A.W.M. Paantjens ... [et al.] -- Surgical aspects of lung transplantation / Silvana Marasco ... [et al.] -- Neurologic complications of lung transplantation / Sasha Zivkovic -- Leucocyte intracellular cytokines in lung transplantation patients : a more physiological indicator of immunosuppression than plasma drug levels / Gred Hodge ... [et al.] -- Measurement of intracellular cytokines to improve therapeutic monitoring of immunosuppressive drugs following lung transplantation / Greg Hodge ... [et al.]. 330 $aLung transplantation (LT) is the only definitive treatment for many forms of end-stage pulmonary diseases. However, its success is limited by several factors including organ infection/disease, acute rejection and chronic allograft dysfunction. Progresses made in patient selection, surgical techniques as well as in therapeutic management (immunosuppressive regimes) have led to a growing increase in the one-year survival rates up to 75%, however, the 5-year survival rate following LT remains only approximately 50%. This book presents research in the study of lung transplantation, including primary graft dysfunction in lung transplantation; the impact of viral pathogens in lung transplant patients; neurologic complications of lung transplantation; intensive care management of the lung transplantation patient and the surgical issues facing lung transplant surgeons. 410 0$aOrgan Transplantation Research Horizons 606 $aLungs$xTransplantation 606 $aLungs$xDiseases$xTreatment 615 0$aLungs$xTransplantation. 615 0$aLungs$xDiseases$xTreatment. 676 $a617.5/42 701 $aFerguson$b Richard D.$f1953-$01871385 701 $aHolmer$b Craig A$01871386 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910960620403321 996 $aLung transplantation$94480197 997 $aUNINA LEADER 01176nam 2200205zu 450 001 996696262303316 005 20260108111146.0 035 $a(CKB)37901752500041 035 $a(UnM)99899501 035 $a(EXLCZ)9937901752500041 100 $a20250319|1672uuuu || | 101 0 $aeng 135 $aur||||||||||| 200 10$aState Of Christendom: Giving A Perfect And Exact Discovery Of Many Political Intrigues And Secret Mysteries Of State Practised In Most Of The Courts Of Europe : With An Account Of Their Several Claims, Interests, And Pretensions. Formerly Written By That Renowned Sir Henry Vvotton Knight, Ambassadour In Ordinary To The Most Serene Republick Of Venice 210 $cProQuest, UMI$d1672 700 $aWotton$0832135 906 $aBOOK 912 $a996696262303316 996 $aState Of Christendom: Giving A Perfect And Exact Discovery Of Many Political Intrigues And Secret Mysteries Of State Practised In Most Of The Courts Of Europe : With An Account Of Their Several Claims, Interests, And Pretensions. Formerly Written By That Renowned Sir Henry Vvotton Knight, Ambassadour In Ordinary To The Most Serene Republick Of Venice$94499659 997 $aUNISA